Every
second
counts!™

Vanessa

Living with
Recurrent Pericarditis
6/8
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
Read more
5/4
Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
Read more
5/4
Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
Read more

It’s  . Today, right this very moment, we’re hard at work for patients like Vanessa who have a critical therapeutic need. We approach everything we do with a sense of urgency because, for them, we understand the clock is ticking—and every second makes a difference.

 

Learn More

Arcalyst

Featured News

Kiniksa received FDA approval for Arcalyst on March 18, 2021

Read how Kiniksa is advancing science and impacting the lives of patients with devastating diseases.
Learn More

CEO Story

Fighting for a brighter future, one second at a time.

Sanj K. Patel, CEO and Chairman of the Board of Kiniksa Pharmaceuticals, brings more than 25 years of experience in the biopharmaceutical industry to build a company that puts patients first.
Watch Video

Patient Stories

Serving those who
don’t have time to wait.

Living with a debilitating disease brings questions that go far beyond the symptoms—there’s the fear and frustration of not knowing when, or if, there will ever be an answer. That’s why we’re relentless about making every moment matter at Kiniksa: because every second brings us closer to creating a better future for patients. Hear stories from the people who live with the uncertainty of these diseases every day.

hear
Jill's story

Watch Video
Living with
Recurrent Pericarditis

hear
Nadine’s story

Watch Video
Living with
Recurrent Pericarditis

hear
Vanessa's story

Watch Video
Living with
Recurrent Pericarditis

Connect with us on social media for up-to-date news and discoveries.

 

Follow us